SCHEMBL3480434

SCHEMBL3480434

COc1ccc(-c2ccc(S(=O)(=O)NCP(=O)(O)O)s2)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.45
MEN1 O00255 1/20 0.44
PABPC1 P11940 1/20 0.44
KMT2A Q03164 1/20 0.44
TOP1 P11387 1/20 0.40
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
FBP1 P09467 1/20 0.38
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
KDM4E B2RXH2 1/20 0.37
POLB P06746 1/20 0.37
CYP2A6 P11509 2/20 0.37
MKNK1 Q9BUB5 1/20 0.37
MKNK2 Q9HBH9 1/20 0.37
MAP3K8 P41279 1/20 0.36
KCNH2 Q12809 2/20 0.36
PIK3CG P48736 3/20 0.36
PIK3CA P42336 3/20 0.36
PIK3CD O00329 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3480501 0.81 MAPT (0.48) MMP13MEN1KMT2AMMP2MMP9
SCHEMBL14344699 0.75 CA1 (0.51) MMP13MEN1PABPC1KMT2ATOP1
SCHEMBL3480489 0.75 SNCA (0.47) POLB
SCHEMBL16667405 0.74 P2RY14 (0.38) MMP13MMP2MMP9
SCHEMBL3480451 0.73 ATIC (0.46) MMP13MEN1KMT2AMMP2MMP9
SCHEMBL3480347 0.72 MCL1 (0.41) MEN1KMT2ACA1CA2KDM4E
SCHEMBL16667390 0.68 MAP3K5 (0.41) KDM4E
SCHEMBL4427998 0.68 SMN1; SMN2 (0.55) MEN1KMT2A
SCHEMBL3480383 0.68 MAP3K5 (0.32)
SCHEMBL16667192 0.67 MAP3K5 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317625-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE 92229129 QUEBEC INC. (CA) 2010-12-16 US claimed
EP-2024376-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE Merck & Co., Inc. (US) 2009-02-18 EP claimed
WO-2007139729-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2007-12-06 WO claimed
US-20100317625-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE 92229129 QUEBEC INC. (CA) 2010-12-16 US disclosed
EP-2024376-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE Merck & Co., Inc. (US) 2009-02-18 EP disclosed
WO-2007139729-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317625-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE MGAM, BPGM, PPME1 MMP13 2065/4885MEN1 3104/4885PABPC1 4137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.